Clinical Trial: NCT07138755
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | The Third Xiangya Hospital of Central South University |
| Information Provided By: | The Third Xiangya Hospital of Central South University |
| Last Update Posted: | 2026-09-02 |
Study Overview
Brief Summary
To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Official Title
The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Conditions
NSCLC, Sintilimab, Adaptive Radiotherapy
Intervention / Treatment
- Drug: Experimental
Other Study ID Numbers
- R25063
Start Date (Actual)
2025-08-29
Primary Completion Date (Estimated)
2028-12
Study Completion Date (Estimated)
2030-09
Enrollment (Estimated)
35
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | The Third Xiangya Hospital of Central South University |
| Information Provided By: | The Third Xiangya Hospital of Central South University |
| Last Update Posted: | 2026-09-02 |
Study Overview
Brief Summary
To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Official Title
The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Conditions
NSCLC, Sintilimab, Adaptive Radiotherapy
Intervention / Treatment
- Drug: Experimental
Other Study ID Numbers
- R25063
Start Date (Actual)
2025-08-29
Primary Completion Date (Estimated)
2028-12
Study Completion Date (Estimated)
2030-09
Enrollment (Estimated)
35
Study Type
Interventional
Phase
Phase 2